



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Tuesday,
                        12 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    HEALTH AND FAMILY WELFARE






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

532






                                    ANSWERED ON: 
                                

04.02.2022






COVID-19 Vaccines for Emergency Use




Sangamlal Kadedin Gupta













                                                    Locket Chatterjee
                                                








                                                    P.P. Chaudhary
                                                








                                                    Srinivas Kesineni
                                                








                                                    Rajendra Agrawal
                                                












                        Will the Minister of





HEALTH AND FAMILY WELFARE


                        be pleased to state:-















                                                    (a)	The details of the COVID-19 vaccination available for emergency use in India, and the vaccines in the pipeline along with the expenditure incurred on procurement of these vaccines;(b)	the reasons for the delay in approving more vaccines for use in India;(c)	whether the Government is undertaking trails to understand the effects on immunological response of administering disparate vaccine doses to individuals, if so, the details thereof and if not, reasons therefor; (d)	whether the Government is reviewing the latest research for vaccinating children below the age of 15 years, if so, the details thereof; and (e)	whether the Government has formulated any action plan for administering the booster dose to individuals who have earlier been vaccinated with both the doses and if so, the details thereof? 






ANSWER




                                                        THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE(DR. BHARATI PRAVIN PAWAR)(a) to (e) National Regulator i.e. Central Drugs Standard Control Organization (CDSCO) has granted permissions to following vaccines for restricted use in emergency situation as per the New Drugs and Clinical Trials (NDCT) Rules, 2019: 1.	COVISHIELD of M/s Serum Institute of India Pvt. Ltd. for = 18 years age2.	COVAXIN of M/s Bharat Biotech = 12 years age3.	ZyCovD of Cadila Healthcare Limited for = 12 years age 4.	SPUTNIK-V imported by Dr. Reddy’s Lab. Ltd. and manufactured by M/s Panacea Biotec and M/s Hetero Biopharma, for = 18 years age 5.	Moderna imported by M/s Cipla Ltd., for = 18 years age6.	 Janssen Vaccine imported by M/s Johnson & Johnson Pvt. Ltd and manufactured by M/s Biological E Limited, for = 18 years age7.	 CORBEVAX of M/s Biological E Ltd., for = 18 years age8.	COVOVAX of M/s Serum Institute of India Pvt. Ltd., for = 18 years ageThe following COVID-19 vaccines are under various phases of clinical development: 1.	SPUTNIK-LIGHT of M/s Dr. Reddy’s Lab. Ltd (Phase III).2.	Lyophilized mRNA based COVID-19 vaccine of M/s Gennova Biopharma. Ltd. (Phase II/III). 3.	Nasal vaccine of M/s Bharat Biotech (Phase III).4.	Multiple Protein/ Peptide-Based SARS-CoV-2 Vaccine of M/s Aurobindo (Phase II/III).5.	Inactivated Whole-virion virus (Intra-dermal route) of M/s Bharat Biotech (Phase I/II).6.	Inactivated Rabies vector platform Corona Virus Vaccine (rDNA-BBV151) of M/s Bharat Biotech (Phase I).7.	SARS-CoV-2 Recombinant protein subunit vaccine of M/s Reliance (Phase I).The approval of COVID-19 vaccine by the national regulator is dependent on the safety, immunogenicity and efficacy profile of vaccine through non-clinical and clinical trial data generated and there is no delay in approval of the COVID-19 vaccines.National Regulator i.e. Central Drugs Standard Control Organization (CDSCO) has granted permissions to following entities for conduct of clinical trials for administration of mixed vaccine regimen: 1.	M/s Christian Medical College, Vellore to conduct Phase IV study with COVISHIELD and COVAXIN to compare immunogenicity of mixed vaccine regimen. 2.	M/s Bharat Biotech for Phase II clinical trial to evaluate the immunogenicity and safety of BBV152 (COVAXIN) with BBV154 (Adenoviral Intranasal COVID-19 vaccine).As per the recommendation of the National Technical Advisory Group on Immunization (NTAGI), administration of precaution dose has started from 10th January 2022 to those Health Care Workers (HCWs), Front Line Workers (FLWs) and persons aged 60 years & above with comorbidities who have received two doses of Covid-19 vaccines.Any decision on extension of eligible beneficiaries for precaution dose and vaccination of children below 15 years of age is as per the recommendations of The National Technical Advisory Group on Immunization (NTAGI) on the basis of review of available scientific evidences. In the current financial year i.e. 2021-22, INR 35,000 crore has been budgeted for implementation of COVID-19 Vaccination Programme. As on 31st January 2022, an expenditure of INR 27,945.14 crore has been incurred against this allocation which has been utilized for procurement of COVID-19 vaccine for free of cost supply to State/UTs.*******
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113254407







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







